In this case study, I demonstrate that CHCs are present in the blood of one patient with choroidal melanoma, lung adenocarcinoma, and a neuroendocrine tumor of the lung. Furthermore, I hope to show that CHCs decline following definitive treatment to demonstrate the potential of CHCs as a prognostic biomarker across one patient's treatment journey.